Terminated PHASE2 INTERVENTIONAL 2-arm NCT04388683

Inhaled Nitric Oxide for Preventing Progression in COVID-19 (NO-COVID-19)

Prevention of COVID-19 Progression Through Early Administration of Inhaled Nitric Oxide.

Sponsor: Bellerophon

Conditions COVID-19

Updated 9 times since 2020 Last updated: Apr 12, 2022 Started: May 12, 2020 Primary completion: Nov 23, 2020 Completion: Nov 23, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Bellerophon requested study to be stopped.

Other terminated trials from Bellerophon

COPD · Phase EARLY_PHASE1 · Aug 2017

More terminations from Bellerophon

Other COVID-19 trials with similar outcome

Browse all COVID-19 trials

A PHASE2 clinical study on COVID-19, this trial is terminated or withdrawn. The trial is conducted by Bellerophon and has accumulated 9 data snapshots since 2020. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2023 — Jul 2024 [monthly]

Terminated PHASE2
Dec 2022 — Jan 2023 [monthly]

Terminated PHASE2
May 2022 — Dec 2022 [monthly]

Terminated PHASE2

▶ Show 4 earlier versions

Oct 2021 — May 2022 [monthly]

Terminated PHASE2

Status: Active Not Recruiting → Terminated
Mar 2021 — Oct 2021 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Jan 2021 — Mar 2021 [monthly]

Recruiting PHASE2
Jun 2020 — Jan 2021 [monthly]

Recruiting PHASE2

First recorded

May 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bellerophon
Tufts Medical Center

Data source: Tufts Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States